JOAN M. BULL, M.D.; DAVID LEES, M.D.; WILLIAM SCHUETTE; JACQUELINE WHANG-PENG, M.D.; ROSALIE SMITH, R.N.; GAITHER BYNUM, M.D.; E. RONALD ATKINSON, Ph.D.; JOHN S. GOTTDIENER, M.D.; HARVEY R. GRALNICK, M.D.; THOMAS H. SHAWKER, M.D.; VINCENT T. DeVITA Jr., M.D.
Fourteen patients with a variety of neoplasms not responsive to standard forms of therapy underwent whole body hyperthermia for a maximum 4 h at 41.8 °C. This was a phase-l cancer trial designed to develop whole body hyperthermia as an adjuvant to systemic chemotherapy. Intravenous analgesia was used to sedate patients, obviating the need for general endotracheal anesthesia. Hyperthermia was induced by means of a high-flow water perfusion suit. Cardiovascular performance was evaluated using a flow-directed pulmonary artery catheter. Patients developed a twofold mean increase in cardiac index without evidence of cardiac damage by ECG or creatine Phosphokinase (CPK) isoenzymes. An acute fall in serum magnesium and phosphate and an acute rise in arterial pH, serum CPK values, and granulocyte count occurred in all patients. There were no clotting abnormalities. Toxicity included fatigue, diarrhea, nausea, and transient elevations in liver enzymes. Four patients were febrile for 36 h after initial defervescence. Peripheral neuropathy developed in four. These results show that with carefully monitored conditions whole body hyperthermia is feasible.
BULL JM, LEES D, SCHUETTE W, et al. Whole Body Hyperthermia: A Phase-l Trial of a Potential Adjuvant to Chemotherapy. Ann Intern Med. 1979;90:317–323. doi: https://doi.org/10.7326/0003-4819-90-3-317
Download citation file:
Published: Ann Intern Med. 1979;90(3):317-323.
Cardiology, Coronary Risk Factors, Hematology/Oncology, Prevention/Screening.
Results provided by:
Copyright © 2020 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use